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Abstract: In this review we provide a systematic analysis of transcriptomic signatures derived from 42 breast cancer gene expression 
studies, in an effort to identify the most relevant breast cancer biomarkers using a meta-analysis method. Meta-data revealed a set of 
117 genes that were the most commonly affected ranging from 12% to 36% of overlap among breast cancer gene expression studies. 
Data mining analysis of transcripts and protein-protein interactions of these commonly modulated genes indicate three functional mod-
ules significantly affected among signatures, one module related with the response to steroid hormone stimulus, and two modules related 
to the cell cycle. Analysis of a publicly available gene expression data showed that the obtained meta-signature is capable of predicting 
overall survival (P , 0.0001) and relapse-free survival (P , 0.0001) in patients with early-stage breast carcinomas. In addition, the 
identified meta-signature improves breast cancer patient stratification independently of traditional prognostic factors in a multivariate 
Cox proportional-hazards analysis.
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Introduction
Development of effective tools such as DNA microar-
rays for monitoring gene expression on a large scale 
has resulted in the discovery of gene networks and reg-
ulatory pathways in various tumor processes. In this 
respect, global gene expression in breast cancer has 
been profiled extensively over the last decade, which 
allowed the identification of breast cancer molecu-
lar subtypes and the development of prognostic and 
predictive gene signatures, resulting in an improved 
understanding of the heterogeneity of breast cancer.
In pioneering work, Perou et al used cDNA arrays 
to test the expression of approximately 8,000 genes 
in samples from 42 breast cancer patients1. This first 
report suggested that primary breast carcinomas 
could be classified into specific ‘intrinsic subtypes’ 
distinguished by particular gene expression patterns. 
These data were confirmed and extended by Sorlie 
et al., who investigated the clinical usefulness of the 
breast cancer subtypes identified by screening for 
correlations between gene expression patterns and 
clinically relevant parameters. They demonstrated 
that classification of tumors based on gene expres-
sion patterns could be used as a prognostic marker 
with respect to overall and relapse-free survival 
in a subset of patients who had received uniform 
therapy.2,3 The five subtypes identified (Luminal A, 
Luminal B, Basal-like, ERBB2 positive/ER negative 
and normal breast-like) represent different biological 
entities and might originate from different cell types. 
One of the five subtypes was characterized by over-
expression of ERBB2 and poor prognosis. A second 
tumor subtype, lacking expression of estrogen recep-
tor α (ER) and also with a poor clinical prognosis, 
has been termed “basal,” as it resembles the pattern 
found in basal epithelial cells of the normal mam-
mary gland. This basal tumor type differs from two 
other subtypes, luminal A and luminal B subtypes, 
both of which are ER positive and resemble cells that 
line the duct and give rise to the majority of breast 
cancers.2,3 Additionally, much work has been done on 
the hormonal status of breast cancers; DNA microar-
ray and SAGE (Serial Analysis of Gene Expression) 
studies have focused on the ability of these gene pro-
filing techniques to accurately discriminate ERα(+) 
from ERα(-) phenotypes.4–7 Furthermore, various 
laboratories have identified gene expression signa-
tures that correlate with prognosis and can be used to 
predict the risk of disease recurrence and outcome in 
breast cancer patients.8,9
According to Sotiriou and Pusztai,10 global gene 
expression profiling has employed three different 
strategies to develop genomic signatures that may 
provide better prediction of clinical outcome. First, in 
the ‘top-down’ approach, gene expression data from 
tumors (or cell line models) are correlated with the 
clinical outcome of patients to identify prognostic 
gene signatures (eg, 70- and 76-gene poor-prognosis 
signatures). Second, in the ‘bottom-up’ approach the 
prognostic predictor is derived from a gene expres-
sion signature related to a biological pathway or pro-
cess (eg, wound-response, invasiveness and stromal 
related poor-prognosis signatures). Third, in the can-
didate-gene list approach a set of biomarkers are pro-
spectively selected on the basis of previous biological 
knowledge (eg, recurrence score signature)10.
Among the myriad of prognostic or predictive gene 
expression signatures generated, only four genetic 
assays have been currently licensed for commercial 
use: the 70-gene ‘poor-prognosis’ signature (Mam-
maPrint, Agendia BV, Amsterdam), the 21-gene 
‘recurrence score’ signature (Oncotype DX, Genomic 
Health, Redwood City, California), the 97-gene 
‘genomic grade index’ signature (MapQuant Dx, Ipso-
gen, Marseille, France), and the 2-gene ratio signa-
ture (Theros, Biotheranostics, San Diego,  California). 
Some of these signatures have been previously com-
pared. Fan et al demonstrated that 5 gene expression 
signatures, the intrinsic subtypes, the 70-gene, the 
2-gene expression ratio, the 21-gene, and the wound 
response signature, had similar performance in pre-
dicting outcome.11 However, comparisons of the gene 
lists derived from these studies have shown a lim-
ited or zero overlap between signatures. The reasons 
for this disparity have been attributed to differences 
in the group of patient analyzed (ER status, tumor 
grade, stage, etc), in sample preparation (bulk, micro-
dissected, etc.), in microarray platforms (high or low 
coverage of the human genome) and the statistical 
methods used (supervised or unsupervised methods, 
gene selection, construction of the classifiers, etc.). 
In this sense, Ein-Dor et al demonstrated that many 
equally prognostic or predictive gene sets can be 
obtained from the same study.12 These data showed 
that each gene signature identify different molecular 
features, which are predictive of the clinical outcome 
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by looking a partial picture of breast cancer biology. 
More importantly, these data suggest that combining 
multiples gene expression signatures may provide 
an integrated view that would be useful to define the 
most relevant breast cancer biomarkers.
In the present review, we provide a comprehensive 
integration of 42 breast cancer gene expression sig-
natures demonstrating that the overlap between gene 
expression signatures is greater than previously esti-
mated by the comparison of a reduced set of gene lists.11 
In addition, we demonstrate that the gene expression 
meta-signature is a powerful predictor of clinical out-
come in patients with early-stage breast cancers. We 
also discuss the most relevant set of genes recurrently 
identified in these signatures re-analysis.
Materials and Methods
Identification of common gene 
expression features among breast 
cancer signatures
We employed the GeneSigDB (release 2.0) online 
resource (http://compbio.dfci.harvard.edu/ genesigdb) 
for the detection of gene overlapping among breast 
cancer gene expression signatures available in this 
database.13 GeneSigDB is a manually curated and 
standardized (EnsEMBL gene identifiers) database of 
gene expression signatures (n = 957), which focuses 
on cancer and stem cell studies. We selected the most 
relevant gene signatures derived from 42 breast can-
cer gene expression profiling studies (from 2002 to 
2009) (see additional file 1). For the selected signa-
tures, the GeneSigDB web application provide one 
gene per signature heatmap-style plot colored in red 
or grey according to presence or absence of gene 
overlap, respectively.
Data extraction and hierarchical 
clustering
GeneSigDB data management was performed using a 
customizable HEM2TEM (for HeatMap to TExtMa-
trix) java tool developed by us for extracting a plain 
text matrix from the XML/HTML heatmap previously 
described. To enable unsupervised classification and 
illustration of the commonly overlapped genes between 
the 42 breast cancer gene expression signatures, we 
used the Multi Experiment Viewer (MeV 4.5) soft-
ware (http://www.tm4.org/mev/).14 Two-way (by gene 
and by signature) hierarchical clustering was used to 
 examine the relationships among the 42 breast cancer 
gene expression signatures. Hierarchical clustering was 
based on Spearman’s rank correlation distance metric 
and the complete linkage clustering method. Further-
more, we tested whether semantic terms  (signature 
name, platform name or biological process) differed 
across clusters using the Fisher’s exact test. All P 
values were two sided, and P , 0.05 was considered 
 significant. Subsequently, we selected the most fre-
quently overlapped genes by applying a cutoff of 5 gene 
signatures (12% of 42 signatures) to generate the gene 
expression meta-signature for further analysis.
Data mining analysis
For automated functional annotation and classifica-
tion of genes of interest based on Gene Ontology 
(GO) terms, we used the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/)15.
In order to identify the molecular pathways that 
were mainly affected by the meta-signature, we look 
for protein/gene interaction networks in the common 
core of overlapped genes. The protein-protein interac-
tion network was generated using the STRING database 
(‘Search Tool for the Retrieval of Interacting Genes/
Proteins’) (http://string.embl.de/).16 This bioinformatic 
tool was used with the aims to collect, predict and unify 
most types of protein-protein associations, including 
direct and indirect associations. STRING runs a set 
of prediction algorithms and transfers known inter-
actions from model organisms to other species based 
on predicted orthology of the respective proteins.16 In 
order to identify each gene in the database, we used 
both gene names and EnsEMBL gene identifiers in the 
‘protein-mode’ application. The analysis input options 
were ‘co-occurrence’, ‘co-expression’, ‘experiments’, 
‘databases’, and ‘text mining’ data at high confidence 
level of predicted human orthology groups. All of the 
raw data reported as additional files in this article are 
publicly available at the journal web site.
Gene expression meta-signature  
and survival analysis
To further investigate the prognostic value of the gene 
expression meta-signature, we did survival analy-
ses in a publicly available breast cancer microarray 
study. We selected van de Vijver data set due to the 
Abba et al
106 Biomarker Insights 2010:5
biological diversity of breast tumors included in this 
study.17 Briefly, van de Vijver’s data set included 295 
early-stage breast cancer samples (226 ER-positive 
and 69 ER-negative), some of whom were lymph-
node-negative (n = 151) and the others were lymph-
node-positive (n = 144). The patients had all been 
treated by radical mastectomy or breast-conserving 
surgery, followed in some cases by radiotherapy; and 
a fraction of patients had received adjuvant treat-
ment. Data on relapse-free survival (defined as the 
time to a first event) and overall survival were avail-
able for all patients. The gene expression profile was 
derived by researchers from the Netherlands Cancer 
Institute and Rosetta Inpharmatics—Merck using 
Agilent Hu25K oligonucleotide (60mer) microarray 
(Agilent Technologies, Palo Alto, CA—USA). The 
gene expression matrix and the associated clinical 
data were obtained from the Rosetta Inpharmatics 
website17 (http://www.rii.com/publications/2002/
nejm.html).
In an unsupervised analysis, 295 tumor samples 
were grouped by similarity of the 117 gene list meta-
signature by complete linkage clustering by using 
the Multi Experiment Viewer software. The samples 
were segregated into three classes (from Cluster 1 
to  Cluster 3) based on the second bifurcation of the 
clustering dendrogram. In addition, we integrated the 
gene expression meta-signature with four prognostic 
or predictive gene signatures (Intrinsic subtype, Poor-
prognosis, Recurrence Score and Wound Response 
signatures) to evaluate the data set. Tumor classifica-
tion according to the four prognostic or predictive gene 
signatures were stablished based on data provided by 
Fan et al 2006.11 Kaplan–Meier survival curves and, 
log-rank statistics and the Cox proportional hazard 
method were performed by using the SPSS® statistic 
software package (SPSS Inc., Chicago). The multivar-
iate Cox proportional-hazard model included: estro-
gen receptor status (ER-positive vs. ER-negative), 
tumor grade (grade 1 vs. 2 and grade 1 vs. 3), lymph 
node status (LN-negative vs. 1–3 LN-positives and 
LN-negative vs. . 3 LN-positives), age (as a con-
tinuous variable), tumor size (diameter # 2 cm vs. 
diameter . 2 cm), treatment received (no adjuvant 
therapy vs. chemotherapy/hormonal therapy), and 
gene expression meta-signature predictive clusters 
(cluster 1 vs. cluster 2/3). Overall survival and relapse-
free survival were the end points.
Results and Discussion
Based on a novel gene list meta-analysis approach, 
a systematic review of 42 gene signatures of breast 
cancer was performed in order to identify and com-
pare the most relevant breast cancer biomarkers. The 
study approach underwent four phases: (a) detection 
of overlapping genes among the different signatures, 
(b) examination of the relationship between gene 
expression signatures by a two-way unsupervised 
analysis, (c) identification of the molecular path-
ways that are mainly affected by the gene expres-
sion meta- signature followed by (d) validation of the 
gene expression meta-signature’s prognostic value in 
a set of 295 patients with early-stage breast cancers 
obtained from van de Vijver et al study17.
Identification of the gene  
expression meta-signature  
and data mining analysis
Among the 42 gene expression signatures (see addi-
tional file 1), a total of 946 transcripts were identi-
fied as overlapping in more than one study (Fig. 1A, 
Additional file 2). Of the 946 transcripts, 117 genes 
were identified in more than four studies, represent-
ing a set of the most frequents breast cancer biomark-
ers in this analysis (Fig. 1B). Additional file 2 shows 
the most common overlapping genes between breast 
cancer signatures.
Hierarchical clustering analysis of the 42 gene 
expression studies classified the signatures in four 
groups: the intrinsic subtype signatures, the response 
to chemotherapy related signatures, the stromal/
extracellular matrix (ECM) related signatures and 
the signatures enriched in cell cycle genes (Fig. 2). 
It can be clearly seen that related signatures such us 
intrinsic subtypes and ER-alpha status on the one 
hand, or stromal and extracellular matrix signatures 
on the other hand, have a large overlap relative to 
other gene expression signatures. Furthermore, it is 
interesting to note that the most common signatures 
cluster found was associated with the enrichment of 
cell cycle genes (Fig. 2). Non-statistically significant 
associations were detected between signatures clus-
ters and the microarray platforms employed for gene 
expression profiling (P . 0.05).
Gene Ontology annotation of the 117 gene meta-
signature showed that approximately 55% of the 
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transcripts are involved in cell cycle regulation, 13% 
are related to response to steroid hormone stimulus, 
4% are related to extracellular matrix interaction/
remodeling and 3% are related to other signal trans-
duction pathways (Fig. 3A, additional file 2). Addi-
tionally, Figure 3B shows a protein-protein interaction 
network associating the common core of genes across 
gene expression signatures. The graph was gener-
ated employing the STRING on-line resource based 
on high confidence data. STRING is a comprehen-
sive tool integrating protein association information 
with the capability to transfer known interactions 
from model organisms to other species. The gener-
ated graph (Fig. 3B) indicates strong interactions 
among a set of 95 proteins derived from the 117 gene 
meta-signature (81% of coverage). Furthermore, the 
network architecture suggests the existence of three 
functional modules (sets of genes that act in concert 
to carry out a specific function): a module related 
with the response to steroid hormone stimulus (green 
circles in Fig. 3B), and two modules related with the 
cell cycle signaling pathway (Fig. 3B).
Gene expression meta-signature 
analysis and its clinical relevance  
as prognostic marker
To further explore the prognostic value of gene 
expression meta-signature, we performed univariate 
and multivariate analysis of 295 breast cancer patients 
obtained from a publicly available breast cancer gene 
expression data set.17 We first used hierarchical clus-
tering (HCL) analysis to separate the patients into 
groups according the similarity in the gene expres-
sion meta-signature, and then determined the overall 
and relapse-free survival rates for these groups.
The HCL analysis classified the patients into 3 
clusters (Fig. 4A). To further elucidate the reasons 
driving the separation of breast carcinomas in three 
major groups, we integrated the gene expression 
meta-signature with four prognostic or predictive 
gene signatures (Fig. 4B–C). Interestingly, meta-
signature cluster 1 was highly associated with nor-
mal-like and luminal A breast carcinomas intrinsic 
subtypes (P , 0.0001), cluster 2 was associated to 
luminal B and HER2+/ER- subtypes (P , 0.0001), 
and the meta-signature cluster 3 was mainly com-
posed by basal-like breast carcinomas (P , 0.0001) 
(Fig. 4B). The meta-signature clusters 2 and 3 
were also correlated with breast carcinomas that 
expressed the 70-gene poor-prognosis signature, 
the high recurrence score signature and the acti-
vated wound-response signature (P , 0.0001) 
(Fig. 4C). In addition, we identified important clin-
ico-pathological variables that highly correlated 
with the meta-signature clusters such as: ER status 
(P , 0.0001), tumor grade (P , 0.0001), and tumor 
size (P = 0.003) (Fig. 4D).
Kaplan–Meier analysis revealed that the meta-
signature cluster 2 and 3 were particularly associated 
with shorter overall survival (P = 2.90E-11; Fig. 5A) 
and relapse-free survival (P = 2.79E-9; Fig. 5B) 
comparing with the cluster 1. In addition, the meta-
signature and the 70-gene poor prognosis signature 
were the most predictive models in the comparative 
analysis of their Kaplan–Meiers survival curves as 
reflected by their having the lowest nominal P-values 
(Fig. 5 A–J).
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Figure 1. Overlap beween gene identifiers across 42 breast cancer gene 
expression signatures. A) Heatmap representation of 946 genes overlap-
ping in more than one gene expression signature. B) Heatmap represen-
tation of 117 genes overlapping in at least 5 out of 42 gene expression 
signatures analyzed. easch row is a gene and each column is a breast 
cancer gene expression signature. Presence of a gene is indicated by a 
blue box, and absence is white.
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To further evaluate the independent prognostic 
value of the gene expression meta-signature, we next 
performed a multivariate Cox proportional-hazard 
analysis that included the most relevant and tradi-
tional prognostic factors such as: ER status, tumor 
grade, nodal status, tumor size, etc. This analysis 
demonstrated that the gene expression meta-signature 
was statistical significant predictor of both overall 
survival and relapse-free survival (Table 1).
The results show that the 117-gene meta-signature 
was highly informative in identifying patients with 
good and poor prognosis outcome based on the expres-
sion profiles obtained from van de Vijver data set.17 In 
addition, the meta-signature added important prognos-
tic information beyond that provided by the standard 
clinical predictors. In fact, the meta-signature was the 
most predictive variable in the analysis as reflected 
by their having the lowest nominal P-values (see 
Table 1). We identify the most representative differ-
entially expressed transcripts between meta-signature 
clusters using a supervised statistical method (ANOVA 
test). The most statistically significant transcripts up- 
regulated between clusters are represented in Table 2.
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Figure 2. Hierarchical clustering analysis of the 42 breast cancer gene expression studies, classified them in four groups: the intrinsic subtypes, response 
to chemotherapy, stromal/extracellular matrix (eCM) and signatures enriched in cell cycle genes. It can clearly be seen that related signatures such us 
intrinsic subtype and eR-alpha status on the one hand, or stromal and extracellular matrix signatures on the other hand, have a large overlap relative to 
other gene expression signatures.
Gene expression modules associated 
with the meta-signature
Response to steroid hormone stimulus module
Approximately two-thirds of all breast cancers are 
ERα(+) at the time of diagnosis and the expression of 
this receptor is determinant of a tumor phenotype that 
is associated with hormone-responsiveness. Patients 
with tumors expressing ERα have a longer disease-free 
interval and overall survival than patients with tumors 
that lack ERα expression.18 Several studies have been 
carried out using cDNA and oligonucleotide microar-
rays identifying breast cancer subclasses possessing 
distinct biological and clinical properties.1,19 Among 
the distinctions made to date, the clearest separation 
was observed between ERα (+) and ERα (-) tumors. 
It has been suggested that there are sets of genes 
expressed in association with ERα that could play an 
important role in determining the  hormone-responsive 
breast cancer phenotype.20 Functional annotation of 
the 117 gene meta-signature identified several genes 
related to the response to steroid hormone stimulus, 
such us ESR1 (ERα), XBP1, FOXA1, GATA3, MUC1, 
TFF3, BCL2, etc. The expression of this gene set has 
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Figure 3. Data mining analysis of the gene expression meta-signature. 
A) Gene ontology (GO) classification of the 117 gene list meta-signature 
with specific gene ontology annotations based on biological processes or 
molecular function terms. B) Graph of protein-protein interactions among 
the 117 gene expression metasignature generated using the STRING 
database. In the network: links between proteins means the various inter-
actions data supporting the network, colored by evidence type.
been shown to correlate with a specific breast cancer 
phenotype, defined as luminal type A, carrying an 
improved disease-free survival and overall survival 
when is compared with tumors that do not express 
it. The XBP1 transcription factor is an estrogen-
 regulated gene that is known to augment ER-mediated 
transcription itself, thereby initiating a feed-forward 
pathway.21,22 FOXA1 encodes a transcription factor 
protein that is known to bind to condensed hetero-
chromatin via its winged helix DNA binding domains, 
functioning as a major factor to facilitate subsequent 
association of ER with chromatin of estrogen-target 
genes (eg, TFF1, XBP1 genes).23 Recently, it was 
demonstrated that GATA3 is required for estradiol 
stimulation of cell-cycle progression of breast can-
cer cells. GATA3 binds to cis-regulatory elements 
located within the ESR1 promoter, and this is required 
for transcriptional modulation of the ESR1 gene. 
 Reciprocally, ERα directly stimulates transcription of 
the GATA3 gene, indicating that these two factors are 
involved in a positive cross- regulatory loop.24 It has 
been reported that GATA3 may be involved in growth 
control and differentiation of breast epithelial cells 
mediating the transcriptional activation of several 
genes such as those encoding cytokeratins 5, 6 and 
17, and trefoil factors 1 and 3.25 Parikh and colleagues 
(2005) suggested that GATA3 expression might be 
associated with responsiveness to hormone therapy in 
breast cancer patients.26 Moreover, some of the genes 
in the cluster are ERα/GATA3–regulated genes such 
as MUC1, TFF3, and FOXA1, thus showing the func-
tional clustering of a transcription factor and some of 
its direct targets.5 In this sense, we previously dem-
onstrated that GATA3 is a mediator for the transcrip-
tional up-regulation of MUC1 oncogene expression in 
some breast cancers.27 MUC1 gene encodes a highly 
glycosylated protein located on the apical surface of 
mammary epithelia that is aberrantly over-expressed 
in approximately 90% of human breast cancers.28,29 
MUC1 protein over-expression has been associated 
with cell adhesion inhibition as well as increased 
metastatic and invasive potential of tumor cells. This 
over-expression allows MUC1 to interact with mem-
bers of the ERBB family of receptor tyrosine kinases 
30 In addition, the MUC1 cytoplasmic domain, which 
comprises the last 72-aa, also interacts with diverse 
effectors that have been linked to transformation, such 
as c-Src, β-catenin, and IKβ/NF-KB.30–32 Interest-
ingly, MUC1stimulates ERα-mediated transcription 
by direct binding to the ERα DNA binding domain 
and contributes to E2- mediated growth and survival 
of breast cancer cells.33 It has also been shown that 
MUC1 levels can be regulated by estrogen since ERα 
can bind to putative binding sites derived from the 
MUC1 promoter in-vitro.34 The identified module 
across gene expression signatures may be of value as 
breast cancer prognostic or predictive indicators ana-
lyzed as a group, playing an important role in control-
ling ER-E2-mediated effects in breast cancer cells. 
It is also likely that groups of co-regulated genes in 
ERα (+) breast cancers may be associated to the hor-
monal control of mammary epithelial cells growth and 
differentiation. In addition, a better understanding of 
the signaling networks controlled or associated with 
the estrogen response may lead to the identification of 
novel breast cancer therapeutic targets.
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Figure 4. Cross-validation of the gene meta-signature with a single data set of 295 breast cancer samples and integration with 4 pronostic or predictive 
gene expression signatures. A) Meta-signature hierarchical clustering, cluster 1 (blue), cluster 2 (pink), cluster 3 (orange). Gene ontology clustering (left of 
the graph), the green bar indicates genes related to steroid hormone stimulus, the blue bar indicates cell cycle related genes. B) Intrinsic Subtype signa-
ture. c) Poor prognosis signature: good prognosis (blue), poor prognosis (orange); Recurrence score: high (orange); intermediate (blue light), low recur-
rence score (blue) and wound response: activated (orange); quiescent (blue). D) Clinicopathological data. estrogen Receptor (eR) status: positive (black) 
and negative (white). Histological grade: high (black); moderate (grey) and low grade (light grey). Lymph node (LN) status: negative (white); 1–3 positive 
(grey); .3 positive (black). Tumor size: #2 cm (grey) and .2 cm (black).
Cell cycle module and the mitotic  
spindle related genes
A common observation in cancer gene expression pro-
filing is the systematic up-regulation of  proliferation/
cell cycle related genes among human cancer cells. 
The up-regulation of these genes is consistent with 
the fact that cancer is a disease that disrupts normal 
cell cycle control. Moreover, both in interphase and 
during mitosis, surveillance mechanisms (check-
points) ensure that cell cycle events occur in the 
correct order by delaying crucial transitions until 
previous processes have been completed. Lesions 
in the processes and checkpoints mentioned above 
inevitably lead to genetic imbalances, a hallmark of 
cells in most solid tumors.
As was previously described, functional annotation 
of the 117 gene meta-signature identified 64 genes 
related to the cell cycle process. In addition, accord-
ing to the gene/protein network analysis the 64 genes 
were divided in two modules: 32 genes (50%) related 
to the mitotic spindle biology and 32 genes (50%) 
related with cell cycle progression per se (red circles 
and part of blue circles in Figure 3, respectively). 
More importantly, the mitotic spindle module con-
sists of 32 genes of which many have been associ-
ated with gene over-expression and poor prognosis in 
breast cancer such as PTTG1, ESPL1, TOP2A, NEK2, 
AURKA, TPX2, PLK1, etc.
PTTG1 also called securin gene encodes an 
anaphase-pomoting complex (APC) substrate that 
associates with a separin (ESPL1) until activation 
of the APC. In human tumours, high securin expres-
sion has been related to increased cell proliferation 
and angiogenic phenotype.35,36 Although the role 
of securin in breast carcinoma is not thoroughly 
studied, Solbach et al (2004)37 published an ini-
tial observation on securin mRNA over-expression 
in association with lymph node involvement and 
tumor recurrence. According to this study, the most 
significantly  deregulated proliferation-associated 
genes were securin and topoisomerase DNA II alpha 
(TOP2A), other of the cell cycle module genes. 
TOP2A is located close to ERBB2 on chromosome 
17q12 and copy number changes of TOP2A have 
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frequently been linked to ERBB2 amplified breast 
cancers.38
Interestingly, in another study it has been dem-
onstrated that BRCA1 regulates transcriptional 
expression of multiple cell cycle genes, including the 
genes mentioned above PTTG1 and ESPL1 as well 
as NEK2, BUB1, PLK1 and the progression genes 
CDC2 and CDC20. In this sense, it was demonstrated 
that NEK2 plays a critical role in carcinogenesis, 
tumor invasion, and tumorigenic growth of breast 
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Figure 5. Kaplan–Meier curves of overall and relapse-free survival among the 295 early-stage breast cancer patients obtained from van de vijver et al 
study (2002) according to the meta-signature (A and B), Intrinsic Subtypes (c and D), Poor Prognosis Signature (e and F), Recurrence Score (G and H) 
and wound Response (I and J).
Table 1. Multivariate Cox proportional hazard analysis of standard clinical prognosis factors with the gene expression meta-
signature predictor.
Variable* Overall survival Relapse-free survival
Hazard ratio (95% cI) P-value Hazard ratio (95% cI) P-value
Age, per decade 0.68 (0.46–1.01) 0.056 0.57 (0.41–0.79) 0.001
eR status 0.64 (0.39–1.05) 0.076 0.93 (0.60–1.45) 0.763
Tumor grage 2 vs. 1 3.25 (1.10–9.60) 0.033 1.66 (0.88–3.13) 0.120
Tumor grade 3 vs. 1 2.69 (0.90–8.01) 0.076 1.37 (0.70–2.68) 0.358
Size 1.71 (1.05–2.79) 0.031 1.47 (1.01–2.16) 0.045
Lymph node 1–3 (+) vs. 0 0.95 (0.44–2.05) 0.904 1.13 (0.63–2.04) 0.683
Lymph node . 3 (+) vs. 0 1.77 (0.75–4.21) 0.195 2.04 (1.01–4.13) 0.047
Treatment 0.83 (0.39–1.76) 0.622 0.55 (0.30–1.00) 0.049
Meta-signature 5.18 (2.33–11.5) 5.5e-5 3.18 (1.91–5.31) 9.5e-6
notes: *Size was a binary variable (0 = diameter of 2 cm or less, 1 = greater than 2 cm.), age was a continuous variable formatted as decade-years. 
Hazard ratio for meta-signature was calculated comparing the clusters 2 and 3 relative to cluster 1. Variables found to be significant (P , 0.05) in the Cox 
proportional hazard model are shown in bold.
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carcinoma, and that inhibition of NEK2 expression 
with siRNA causes suppression of cancer growth and 
invasion in both ER(+) and ER(-) cells.39 Another 
mitotic spindle related gene that has gained interest 
recently is AURKA (Aurora Kinase A). AURKA has 
well-established but perhaps not yet fully understood 
roles in centrosome function and duplication, mitotic 
entry, and bipolar spindle assembly. By the G2 phase 
of the cell cycle through anaphase, it can be detected 
in the pericentriolar material. Additionally, it spreads 
to mitotic spindle poles and midzone microtubules 
during metaphase.40 In a wide range of tumor types 
compared with essentially non-proliferating matched 
normal tissue, AURKA is strongly expressed at high 
frequency. This high level of expression is often asso-
ciated with amplification of the region of chromosome 
20 encoding AURKA.41 A number of recent findings 
have considerably advanced our understanding of 
the regulation of AURKA. The first insight came 
when a search for proteins interacting with AURKA 
revealed TPX2 as a prominent interaction partner of 
this kinase in mitotic human cells.42 TPX2 is not only 
a prominent component of the mitotic spindle,43 but 
also a key player in a spindle assembly process that is 
regulated by the small GTPase Ran.44 After the break-
down of the nuclear envelope, inactive cytoplasmic 
AURKA is transported to the proximal ends of the 
microtubules and activated by the spindle protein 
TPX2, where it plays an as yet not fully defined role 
in the Ran spindle assembly process.40,45 AURKA is 
also linked to the process of G2-M transition, with 
suppression of expression leading to G2-M arrest and 
Table 2. Most highly up-regulated transcripts from meta-siganture gene list in van de vijver et al 2002 data set.
Gene name entrez ID F-ratio Biomarker
Response to steroid hormone stimulus
FOXA1 (forkhead box A1) 3169 518.77 Cluster 1
GATA3 (GATA binding protein 3) 2625 167.42 Cluster 1
ESR1 (estrogen receptor 1) 2099 152.04 Cluster 1
XBP1 (X-box binding protein 1) 7494 141.47 Cluster 1
Cell cycle and mitotic spindle
CENPA (centromere protein A) 1058 243.97 Cluster 3
BUB1 (budding uninhibited by benzimidazoles 1 homolog) 699 234.41 Cluster 3
HJURP (Holliday junction recognition protein) 55355 230.73 Cluster 3
CCNB2 (cyclin B2) 9133 227.29 Cluster 3
KIF2C (kinesin family member 2C) 11004 213.76 Cluster 3
KIF20A (kinesin family member 20A) 10112 202.88 Cluster 3
CDC20 (cell division cycle 20 homolog) 991 187.72 Cluster 3
PRC1 (protein regulator of cytokinesis 1) 9055 183.64 Cluster 3
CEP55 (centrosomal protein 55 kDa) 55165 182.11 Cluster 3
FOXM1 (forkhead box M1) 2305 169.99 Cluster 3
UBE2C (ubiquitin-conjugating enzyme e2C) 11065 167.93 Cluster 3
CDCA8 (cell division cycle associated 8) 55143 167.46 Cluster 3
KIFC1 (kinesin family member C1) 3833 161.72 Cluster 3
AURKA (aurora kinase A) 6790 155.97 Cluster 3
TTK (TTK protein kinase) 7272 149.15 Cluster 3
CENPN (centromere protein N) 55839 147.54 Cluster 3
MAD2L1 (MAD2 mitotic arrest deficient-like 1) 4085 141.72 Cluster 3
BIRC5 (baculoviral IAP repeat-containing 5) 332 141.26 Cluster 3
KIF14 (kinesin family member 14) 9928 136.10 Cluster 3
CCNA2 (cyclin A2) 890 130.65 Cluster 3
PTTG1 (pituitary tumor-transforming 1) 9232 126.93 Cluster 3
Metabolism and Miscellaneous 
MELK (maternal embryonic leucine zipper kinase) 9833 194.99 Cluster 3
CTPS (CTP synthase) 1503 145.28 Cluster 3
EZH2 (enhancer of zeste homolog 2) 2146 132.67 Cluster 3
SOD2 (superoxide dismutase 2, mitochondrial) 6648 127.96 Cluster 3
TRIP13 (thyroid hormone receptor interactor 13) 9319 126.41 Cluster 3
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apoptosis and ectopic expression leading to bypass 
of the G2-M DNA damage-activated checkpoint in 
model systems.46,47 In this sense, AURKA also regu-
lates the activity of the PLK1 enzyme. One of PLK1’s 
important early mitotic functions is to activate 
CDK1.48 Recent work in mammalian cells revealed 
that phosphorylation of PLK1 by AURKA leads to 
the burst of PLK1 activity at the G2-M transition and 
efficient entry into mitosis and ensures timely entry 
into mitosis.49 Moreover, the adaptation and recovery 
functions of PLK1 take place at the G2-M transition, 
when PLK1 activity starts to increase.48 Thus, suc-
cessful resumption of cell cycle progression at G2-M 
and mitotic entry relies on the activation of PLK1 by 
AURKA mediated phosphorylation within the acti-
vation loop of PLK1.49 Also, PLK1 is overexpressed 
in human tumors and has prognostic potential in can-
cer, indicating its involvement in carcinogenesis and 
its potential as a therapeutic target. In breast cancers, 
PLK1 has been found to be highly expressed in prein-
vasive in situ carcinomas.50 Several PLK1 inhibitors 
are in different phases of clinical development for 
anticancer  therapy.51 As we have mentioned before, 
PLK1 activates CDK1, which has been strongly asso-
ciated with breast cancer clinical outcome especially 
for node negative cancer patients.52 Following with 
the mitotic spindle module genes, PLK1 can enhance 
the transcription of multiple proteins necessary for 
mitotic progression via its effect on FOXM1.53–55 
As the genes mentioned before, FOXM1 transcrip-
tion factor is involved in the G2-M phase of the cell 
cycle. Consistent with a role in proliferation, elevated 
expression of FOXM1 has been reported in basal 
cell carcinoma.56 Furthermore, analysis of microar-
ray data from primary breast cancers revealed that 
FOXM1 expression is increased in infiltrating duc-
tal carcinoma.55 Microarray data from cells treated 
with FOXM1 siRNA identified several genes that are 
regulated by FOXM1, including CENPA, NEK2, and 
KIF20A, which also belong to the identified mitotic 
spindle module genes.57 FOXM1 also plays a role in 
regulating G2-M by inducing expression of cyclin A 
and CDC25B. Cyclin A binding to CDK1 promotes 
entry into mitosis, whereas CDC25B dephosphory-
lates CDK1, thereby promoting CDK1 activity58.
Interestingly, the centromere associated protein 
family members, the mentioned CENPA, CENPN, 
CENPE and CENPF are all linked in the spindle 
module gene. CENPA is essential for the recruitment 
to the centromere of most other proteins required for 
kinetochore function,59 as indicated by the observa-
tion that RNAi of CENPA causes a failure of chromo-
some alignment at the metaphase plate.57 Although 
there is no enough information about gene expres-
sion and prognosis of CENPA, CENPN and CENPE 
in breast cancer, CENPF expression has been asso-
ciated with poor prognosis and chromosomal insta-
bility in patients with primary breast cancer. Little is 
known about the function of CENPF in cancer, but it 
has been examined its association with other known 
tumor parameters.60 It is known that normal kineto-
chore accumulation of CENPF follows the recruit-
ment of BUB1 that first localizes to outer and inner 
kinetochore plates in a BUB3 dependent manner.61,62 
This is followed by kinetochore accumulation of 
BUBR1, CENPE, and MAD2.63,62 Systematic silenc-
ing of kinetochore components with RNAi has been 
used to examine the interdependencies in the kine-
tochore assembly pathway. It has been noted that the 
order of assembly reflects the requirement of inter-
action between early and late associating proteins.64 
Depletion of CENPF has been reported to decrease 
the amount of CENPE,64,65 BUBR1, and MAD1 at the 
kinetochores, suggesting that CENPF may modulate 
kinetochore maturation and function.53 Moreover, 
the Forkhead transcription factor FOXM1 as well 
as the other mentioned G2-specific genes NEK2, 
KIF20 and CENPA, regulates expression of CENPF. 
The interdependency between CENPF and BUBR1 
is further supported by the observation that deple-
tion of ZWINT, a structural component of the kine-
tochore, reduces the amount of kinetochore-bound 
CENPF and BUBR1.66 CENPF also associates 
with CENPE, a known activator of the kinetochore 
bound BUBR1.67 The mentioned CENPF associ-
ated genes, BUBR1 (BUB1), MAD2 (MAD2L1) and 
ZwINT are also members of the spindle module 
genes. Except ZwINT, whose role has not been well 
characterized, these genes along with other spindle 
checkpoint genes have shown increased expression 
in breast carcinomas, which was associated with 
genetic instability.68,69 Finally, the other members 
of the mitotic spindle gene cluster are also closely 
related; the kinesin KIF20, for instance, is a target 
for PLK170 CEP55, a protein associated with the 
centrosome directly interacts with KIF23,71 PRC1 
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a protein involved in cytokinesis, which is at high 
level during S and G2-M interacts with KIF2C sug-
gesting that PRC1 might play critical roles in tumor 
cell growth and be a promising target for the devel-
opment of anticancer drugs to breast cancer.72
In view of this information, it is interesting to 
note that most genes of the mitotic spindle cluster 
are involved in the G2-M phase of the cell cycle in 
which they are more active. Since these genes arose 
from a breast cancer gene signature meta-analysis of 
42 studies, it is possible to believe that these genes, 
involved in “opening the door to proliferation”, could 
represent potential targets for breast cancer therapy. 
Although many of them have been extensively stud-
ied in breast carcinoma, there are new ones that 
might constitute the “key to close the door”.
The other cluster of cell cycle genes is a more 
heterogeneous group, which mainly includes 
cyclins, cyclin dependent kinases, cyclin dependent 
kinases inhibitors and members of the minichromo-
some maintenance complex (MCM). Several stud-
ies have focused on the behavior and localization 
of different cyclins during tumor progression. Of 
cyclins that emerged from our analysis, cyclins A2, 
B1, B2 and E2 are all well characterized; however 
there is no enough information about their expres-
sion in breast cancer. Cyclin A2 is associated with 
cellular proliferation and can be used for molecu-
lar diagnostic as a proliferation marker. It has been 
demonstrated that this gene is an estrogen-mediated 
down-regulated.73 A recent study, suggested that an 
oncogenic role of overexpressed cyclin B1 is medi-
ated in nuclei of breast carcinoma cells, and the 
nuclear translocation is regulated by PLK1.74 Cyclin 
E2 has been shown to be overexpressed in breast 
cancer although the potential role as a diagnostic 
or prognostic marker is unknown.75 Similarly, little 
is known of MCM genes in breast cancer. Ha et al 
postulated that MCM3 is involved in multiple types 
of human carcinogenesis.76 Recently, MCM2 has 
been proposed as a useful proliferative marker in 
breast cancer.77
conclusions
In summary, microarray technology has allowed the 
discovery of relevant signatures and consequently the 
identification of novel genes that may have an impact 
as breast cancer biomarkers. Our comprehensive 
comparison of overlapping genes across 42 breast 
cancer gene expression signatures provides an inte-
grated view of a significant number of transcripts 
identified as highly modulated in breast tumors. The 
identification of individual proteins is of high rel-
evance not only for the potential value as prognos-
tic biomarkers but also because may provide insight 
into mechanisms and pathways of relevance in breast 
cancer progression. More importantly, this analysis 
identified the most promising biomarkers for further 
evaluation in breast cancer such as the cell cycle and 
mitotic spindle related genes.
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